This isn’t Bertin Nahum’s first surgical robotics rodeo. The CEO of Quantum Surgical previously co-founded, led and ultimately sold surgical robotics pioneer Medtech S.A. to Zimmer Biomet. Now, he’s leading several members of that founding team as Quantum Surgical develops a next generation of surgical robot to enable easier removal of cancerous tumors. Nahum brings great insight and perspective to the topic of surgical robotics, which is why he’ll sit on a panel of surgical robotic company CEOs and provider represents to discuss what surgical robotic systems of the future may look like. Register at DeviceTalks.com. Joining co-hosts Chris Newmarker and Tom Salemi is Danielle Kirsh, senior editor of MassDevice, to review a few of the highpoints of the current Medical Design and Outsourcing issue of the Big 100. We’ll talk about headcounts, R&D spends and CEO salaries. You can find the issue of the Big 100 here. https://www.medicaldesignandoutsourcing.com/september-2023-medtech-big-100-largest-device-companies/ Thanks for listening to the DeviceTalks Weekly Podcast. You can subscribe to the DeviceTalks Podcast Network on any major podcast application.

In this episode of StrykerTalks, Andrés Rosales, VP and General Manager Endoscopy, delves into Stryker's groundbreaking 1788 visualization platform and and its potential to revolutionize surgical procedures. The 1788 visualization platform, Stryker's 26th generation camera, enables surgeons to see more so they can do more by visualizing tissue perfusion and illuminating cancer cells, ultimately improving patient outcomes. Rosales also discusses the newly 510(k) cleared SPY-PHI for lymphatic mapping within breast cancer, offering surgeons a more efficient and patient-friendly alternative to traditional radioactive markers. The innovation continues as Rosales hints at the future of Stryker's technology, emphasizing the role of data collection and algorithm development in improving surgical procedures. Tune in to discover how Stryker is setting new standards in surgical visualization and how Stryker is collaborating with customers to create meaningful tools that improve the patient experience. Thank you to GlobalMed-MDI for sponsoring this episode. To learn more about how GlobalMed-MDI works with medical device companies, visit www.moldeddevices.com. Thank you for listening to the StrykerTalks Podcast. Subscribe to this podcast on every major podcast platform

In this week’s podcast, we’ll visit with John McCutcheon, president and CEO of EBR Systems, which is developing a miniature pacemaker that is powered by ultrasound and located in the left ventricle of the heart. McCutcheon shares his plans for the start-up but more on the point of this week he recalls his experience as CEO of Emphasys Medical, an interventional pulmonology start-up that received a shocking negative recommendation from an FDA panel in 2008. The no vote led to the shutdown and sale of Emphasys, but the rejection ultimately helped convince the FDA and industry to assess their relationship. Ultimately, the two sides improved relations as McCutcheon explains in the podcast. The rejection is somewhat reminiscent of the negative vote issued this week by an advisory panel for Medtronic’s Symplicity Spyral renal denervation (RDN) therapy for hypertension. McCutcheon explains how the negative impact impacted him at the time, but more important how he’s moved on to appreciate the experience. Thanks for listening to the DeviceTalks Podcast Network. Subscribe to the DeviceTalks Podcast Network on any major podcast application.

In the newest episode of AbbottTalks, Vish Charan, divisional VP of product development at Abbott, takes us through the inner workings of the recently FDA-approved AVEIR™ DR Dual Chamber Leadless Pacemaker System, from its inception to its successful clinical trial and FDA approval. Charan also dives deep into the technology, revealing the cutting-edge i2i communication technology that powers AVEIR™ pacemakers, enabling seamless communication between devices for dual chamber pacing and AV synchrony. Finally, Charan discusses the challenges of miniaturization, the remarkable advancements in battery technology that have made the AVEIR™ pacemaker possible, and the potential for further applications in conduction system pacing. As the field of cardiac rhythm management continues to evolve, Charan envisions a future of smaller devices, more features, and enhanced patient care. Make sure to listen in for invaluable insights into the groundbreaking AVEIR™ DR and its potential to transform the landscape of cardiac care. Thank you to Resonant Link for sponsoring this episode of AbbottTalks. For more information about Resonant Link go to www.Resonant-Link.com. Thank you for listening to the AbbottTalks Podcast.

As a thank you for subscribing and listening to the DeviceTalks Weekly Podcast we built a special code to help you register for the Oct. 18-19 DeviceTalks West conference at the Santa Clara Convention Center. Please give a listen! Go to DeviceTalks.com to register now!! Save $300 off the full registration price. Plus, we replay our keynote interview with Intuitive CEO Gary Guthart at last year’s DeviceTalks West event. In this conversation Guthart will provide additional details of Intuitive’s move into endoscopic robotics including the ION robot. He’ll give his assessment of the growing competition in surgical robotics and what it means for Intuitive. Finally, he shares why he thinks the term surgical robotics may have no meaning in the future.

A little over a year after taking over the CEO role at Ambu A/S, Britt Meelby Jensen visits the DeviceTalks Weekly Podcast to draw lessons from her career that led her to lead the single-use endoscope leader last year. At the time, Meelby Jensen says Ambu was missing Wall Street expectations. In this interview, Jensen highlights the benefits of single-use endoscopes, such as improved workflow and reduced waiting times, and emphasizes Ambu's focus on sustainability. She’ll also review the company’s plan to retain its position in the white-hot single-use scope industry. But first Host Tom Salemi take a dive into earnings week with MassDevice Executive Editor Chris Newmarker and Associate Editor Sean Whooley. We won’t dig too deep into the numbers, but instead we’ll ask why Wall Street investors don’t seem too impressed with the performance of some high-flying medical device companies. Join us at DeviceTalks West on Oct. 18-19 for some in-person discussions! Thanks for listening to the DeviceTalks Weekly Podcast. Subscribe to the DeviceTalks Podcast Network on any major podcast application.

This special episode of Boston Scientific Talks brings you DeviceTalks Boston’s keynote conversation with Boston Scientific's executive leaders Meghan Scanlon, President of Urology; Jennifer Saunders, Sr. Manager of Medical Affairs; Ben Cutone, Global Franchise Director of Prostate Health; and Kristin LaRocca, Senior Vice President of Sales. In the conversation, the key figures delve into the innovative strategies and technologies shaping the urology field, highlighting the LithoVue™ Elite Single-Use Digital Flexible Ureteroscope System. They explore how Boston Scientific is addressing care disparities in underrepresented communities, pioneering programs like "close the gap" in cardiology, and advancing accessibility and equality. The conversation also highlights the importance of data-driven decision-making, clinical evidence, and humble dialogue with clinicians to commercialize innovative strategies. The panelists discuss the challenges and rewards of disrupting the market, the role of health economics, and the unique contributions of urologists as innovators. They also touch on commercial modeling and the importance of empathy, self-awareness, and courage in bringing new ideas to life. Tune in to discover how Boston Scientific is not only advancing urological care but also the way the leadership team approaches problems and solutions. Thank you to Clari for sponsoring this episode of Boston Scientific Talks. Go to Clari.com to learn about its unique revenue platform. Thank you for listening to the Boston Scientific Podcast. Subscribe to this podcast on every major podcast platform.

This week's episode features the first of what's sure to be many audio appearances by DeviceTalks Managing Editor Kayleen Brown! We’re also visited by Lisa Carmel and Stephanie Jone, co-chairs of MedtechWomen’s MedtechVISION conference, which is taking place on Sept. 12. They share how the conference's important agenda took shape. Go to MedtechWomen.org to register. Finally, we learn about an exciting new neuromodulation start-up called Motif Neurotech which is developing a tiny, implantable sensor that could advance how TMS therapy is delivered. Steve Goetz, a veteran of Medtronic’s neuromodulation business, explained why he left the giant to join this rising company as chief technology officer. Thanks for listening to the DeviceTalks Weekly Podcast. Subscribe to the DeviceTalks Podcast Network on any major podcast application!

In the newest episode of AbbottTalks, Allen Burton, Divisional VP and Chief Medical Officer of Neuromodulation at Abbott, shares insights into the company's innovative neuromodulation therapies. Burton delves into Abbott's FDA-approved treatment for chronic back pain, which uses electrical stimulation to alleviate pain, improve functionality, and reduce reliance on opioids. Burton discusses Abbott’s recent FDA approval to treat people who suffer from back pain with limited surgical options. He also expands on how the company's pioneering treatment for painful diabetic peripheral neuropathy, a condition affecting millions of Americans. This treatment uses electrical stimulation to dampen painful signals in the feet, enabling patients to regain mobility and control over their lives. Burton further introduces the Eterna SCS System, the smallest neurostimulation system in the market, which offers patients a low charging burden and indications for MRI compatibility. Listen to the full episode to hear directly from Abbott's Neuromodulation CMO on how Abbott's patient-centric neuromodulation therapies are impacting the lives of patients suffering from chronic pain and diabetic peripheral neuropathy. Thank you to Resonant Link for sponsoring this episode of AbbottTalks. For more information about Resonant Link go to www.Resonant-Link.com. Thank you for listening to the AbbottTalks Podcast.

In this episode, Host Tom Salemi learns the Elixir Medical story from CEO Motasim Sirhan, who has spent most of his medtech career developing new vascular implants to prop open previously occluded blood vessels. Sirhan led developing of early version of bare metal stents while at Guidant. He’d go on to start and sell a company that developed another vascular device before pairing with Invus Group to start Elixir Medical in 2005. After a false start, the company is collecting promising clinical data for its DynamX vascular scaffolding system. We’ll learn why Sirhan sees this as an leap forward from drug-eluting stents. He also shares stories from his career about taking chances and overcoming fears. This episode is sponsored by DeviceTalks West. Thanks for listening to the DeviceTalks Weekly Podcast. You can subscribe to the DeviceTalks Podcast Network on any major podcast application.